GoodRx, the leading U.S. platform for prescription cost savings, has partnered with Novo Nordisk to provide all strengths of Ozempic and Wegovy pens to eligible self-pay patients for just $499 each month. This collaboration brings down the cost of two of the most commonly requested GLP-1 medications, making them more affordable for people who don’t have enough insurance coverage. For the first time, Ozempic is now available at this self-pay price through GoodRx.
Health Technology Insights: Zifo Launches AI App for Antibody Discovery on Snowflake
Wendy Barnes, President and CEO of GoodRx, stated, “The demand for GLP-1 medications has reached an all-time high, but many Americans still struggle to get access to them. By working with Novo Nordisk, we’re making a big step toward making these innovative brand-name treatments more accessible for millions of people who need them. It’s a strong example of how the GoodRx platform can offer savings on a large scale—helping to close coverage gaps and ensuring more people can receive the care they need.”
Last year, nearly 17 million people visited GoodRx to find information on GLP-1 costs and savings—a 22% increase from the previous year. GoodRx’s expanded reach has made it more effective than ever at helping individuals navigate the healthcare system and get these medications faster.
Health Technology Insights: AvodahMed and Pulse4Pulse Team Up for AI Preventative Care
Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc., added, “Improving access to effective FDA-approved treatments is a key part of our mission. Our collaboration with GoodRx allows us to connect with those looking for savings and support through a trusted and well-established platform. This initiative lets us meet GoodRx patients where they are with our authentic GLP-1 medicines and also helps launch the new Ozempic self-pay offer for type 2 diabetes patients at an unmatched price.”
Even though more people are using these groundbreaking treatments for type 2 diabetes and obesity, insurance coverage still presents a major obstacle, especially for GLP-1 use related to weight loss. GoodRx data shows that 19 million Americans don’t have insurance coverage for GLP-1s intended for weight loss. By addressing this gap, GoodRx aims to improve access to treatment and speed up the process for those who need it most.
Starting today, qualified patients can use GoodRx to self-pay for Ozempic and Wegovy pens at $499 per month at more than 70,000 retail pharmacies across the country.
Health Technology Insights: Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
